Navigation Links
Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
Date:2/9/2011

t Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended September 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Mucinex® is a registered trademark of Reckitt Benckiser, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(973) 355-8141Media:Charlie Mayr(973) 355-8483
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
2. Watson Confirms Welchol® Oral Suspension Patent Challenge
3. Watson Presents Outlook for Continued Long Term Growth
4. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
5. Watson Announces Preliminary Financial Performance for FY 2010
6. Watson to Host Investor Day on January 21 in New York City
7. Watsons Generic Fentora® Receives FDA Approval
8. Watson to Present at the 29th Annual JP Morgan Healthcare Conference
9. Watson Announces Novel Oral Contraceptive Approval
10. Watson and Richter Announce Exclusive License Agreement for Esmya™
11. Watson Confirms Exalgo™ Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Pulmonary Fibrosis Foundation (PFF) and Veracyte, ... the organizations are partnering on a U.S. patient ... with interstitial lung diseases (ILDs), including idiopathic pulmonary ... (INTENSITY) survey will assess the steps and time ...
(Date:8/27/2015)... 27, 2015  QB3@953—a San Francisco ... of California (UC) research institute and biotech accelerator— ... to identify and facilitate collaborations to translate early ... The agreement formalizes a relationship between ... team and creates a new channel for DPAc ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. 27, ... presenting at the Rodman & Renshaw 17th Annual Global Investment ... at the St. Regis Hotel, ORYZON will be represented by ... Dr. Buesa will present this ... at the Fontainebleau Room (2nd Floor).  The company is completing ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
(Date:8/27/2015)... Riverside, CA (PRWEB) , ... August 27, 2015 ... ... its plans to enter the exploding legal marijuana industry with the launch of ... adult consumers of legal marijuana to order products from their smart phones and ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... The Naderi ... now be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The ... Kybella provides permanent results without surgery. Dr. Kulak is the only Board Certified ...
(Date:8/27/2015)... FL (PRWEB) , ... August 27, 2015 , ... ... announce its partnership with Julia Glushko, professional Tennis player for Israel in the ... uses Zensah® Compression for all her training and recovery. , With a focus ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it has ... for $205.68M in cash. , The addition of Cytovance Biologics to ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... in Spanish . , Researchers of the ... University of Granada (Spain) have discovered that extra virgin ... a paper published in the last issue of the renowned ... the bioactivity of polyphenols (this is, natural antioxidants) present in ...
... Patient Care launches fourth-year program that focuses on ... Feb. 5 /PRNewswire/ -- The Partnership ... effort led by southeastern Pennsylvania hospitals and one ... Blue Cross, announces its new initiatives for 2009-2011 ...
... It,s In Our Hands - Has Been Designed ... and Caregivers to Healthcare Resources and Services in ... the initiation of its Community Health Partnership (CHP), ... Bronx area, seeking to link Hispanic residents with ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer, manufacturer and distributor in the People,s ... controlled subsidiary Beijing,Liang Fang Pharmaceutical Co., Ltd. ... million) in December 2008 for land use ...
... MinuteClinic, the pioneer and largest provider of ... that it has become a participating provider in ... South Carolina.BlueCross, Preferred Blue and Medicare Advantage members ... centers located in the Columbia and Greenville markets. ...
... 5 Palomar Medical Technologies, Inc. (Nasdaq: ... systems for cosmetic treatments, today announced financial results for ... Revenues for the quarter ended December 31, 2008 ... revenues, $2.2 million were royalty revenues, $0.5 million were ...
Cached Medicine News:Health News:Spanish scientists confirm extra virgin olive oil helps to combat breast cancer 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 3Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 2Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 2Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 4Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 5Health News:MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: